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J Sex MedIntroduction: Although many studies on the short- and long-term effects of hormonal treatment (HT) in trans
people focus on objective changes such as body composition or bone density, few studies have evaluated
self-reported effects of HT.
Aim: To evaluate self-reported symptoms during the ﬁrst year of HT in trans people.
Methods: This study is part of the European Network for the Investigation of Gender Incongruence, a
multicenter prospective cohort study. For this study, 205 trans women and 193 trans men from the gender
clinics of Amsterdam, Ghent, and Florence, who were >18 years of age and started hormonal treatment were
included. Questionnaires, self-developed based on the Menopause Rating scale and clinical experiences, were
completed, and changes in symptom scores were analyzed using linear mixed models.
Main Outcome Measures: Self-reported psycho vegetative symptoms, as well as physical, cognitive, emotional,
sexual and genital complaints, and pain were evaluated at baseline and after 3, 6, and 12 months of HT using a
4-point Likert scale (no, mild, moderate, or severe complaints).
Results: In trans men, with a median age of 23, transient increases were reported in night sweats, weight gain, and
clitoral pain. Persistent increases were reported for hot ﬂashes, balding, voice instability, acne, and increase in sexual
desire, whereas emotional instability, fear, and menses decreased. For trans women, with a median age of 29, hot
ﬂashes, night sweats, fatigue, weight gain, changes in olfactory sense, brittle nails, emotional instability, mood
swings, and breast tenderness increased persistently during 12 months of HT, whereas a decrease was observed for
balding and sexual desire. Sleeping difﬁculties decreased temporarily. No changes were observed in palpitations,
dizziness, abdominal complaints, anxiety, panic attacks, cognition, and pain, except for clitoral and breast pain.
Clinical Implications: Knowledge on the occurrence of these self-reported, subjective effects and their course
over time may help physicians informing trans people starting with and during HT.
Strengths & Limitations: This study was performed in a large cohort of trans people. The follow-up period was
limited to 12 months.
Conclusion: Changes in self-reported symptoms were mentioned in all investigated areas, except cognition. Most
symptoms were as expected and even desired, whereas others may be considered unpleasant by some trans people.
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1298 van Dijk et alINTRODUCTION
People with gender incongruence have a difference between
their assigned sex at birth and their experienced gender. If this
gender incongruence is persisting and leads to distress, there can
be gender dysphoria.1 People with gender dysphoria, also called
trans people, might desire a gender-afﬁrming treatment, which
includes hormone treatment (HT) with or without surgery. This
therapy reduces gender dysphoria and social distress and increases
the quality of life of trans people.2e5
Trans people assigned female at birth desiring masculinizing
HT, hereafter trans men, can be treated with testosterone to
induce virilization. This includes facial and body hair growth, an
increase in muscle mass and strength, fat redistribution, cessation
of menses, deepening of the voice, clitoral enlargement and
vaginal atrophy.6e8 Trans people assigned male at birth desiring
feminizing HT, hereafter trans women, can receive estrogens and
anti-androgens. This results in a more feminine fat distribution,
breast growth, softening of the skin, a decrease in muscle mass
and strength, a decrease in testicular volume, sperm production,
and spontaneous erections, and a deceleration of hair growth.6,7,9
Besides the desired effects, a variety of undesired effects related
to HT have been reported, such as weight gain or acne in trans
men.10e12 In addition, neuropsychological symptoms, including
sleeping or concentration difﬁculties, mood changes, changes in
sexual desire, and changes in the experience of pain, are
reported.13e19
However, the existing literature is not conclusive about the
incidence of these symptoms. For instance, in trans men, the
reported incidence of acne ranges from 0e94%, 10,13,20 and,
whereas Aloisi et al21 observed headaches in the majority of trans
men, Schlatterer et al13 reported no headaches at all. There are
several possible explanations for the conﬂicting study results.
First, there is a large variation in medication formulations, dos-
ages and administration routes of HT between studies. Next,
(side) effects are measured or scored with different methods.
Furthermore, most studies have a retrospective design or small
study populations, which could have inﬂuenced detection and
incidences of undesirable effects of HT.
Wierckx et al22 prospectively investigated self-reported
symptoms in a small cohort of trans people from Ghent and
Oslo. An increase in sexual desire, voice instability, and clitoral
pain were reported by trans men, whereas trans women reported
breast tenderness, hot ﬂashes, emotional disturbances, and a
decrease in sexual desire.
Therefore, we aimed to prospectively study the development
of self-reported symptoms during the ﬁrst year of HT in a large
population of trans people. We studied this in the areas of psycho
vegetative symptoms, physical complaints, cognition, emotional
and sexual symptoms, genital complaints, and pain. In addition,
we studied whether the symptoms were transient or persisting
during the ﬁrst year of HT, and whether differences between
administration routes of hormonal treatment were present, togather knowledge to inform trans people on the expected
symptoms after starting HT.METHODS
Study population
This study is embedded in the endocrine part of the European
Network for the Investigation of Gender Incongruence project.23
This is an ongoing multicenter prospective study performed in
Amsterdam, Ghent, Oslo, and Florence, evaluating the effects
and side effects of HT in trans people. Trans people aged 18
years who started HT from 2010 onward were eligible for
participation. For the current study, trans people from Amster-
dam, Ghent, and Florence who had completed the ﬁrst treatment
year with estradiol or testosterone by October 2015 (Amsterdam
and Florence) or November 2015 (Ghent) and who had ﬁlled
out 1 questionnaire on symptoms during this year were
included. Questionnaires of participants who had a phased start
with progestogens only and started testosterone later on were
included from the start with testosterone. People were excluded
in case of previous use of HT (including antiandrogen use at
baseline for trans women) or insufﬁcient knowledge of the na-
tional spoken language.
The overall study protocol was approved by the Ethical
Committee of the Ghent University Hospital, Belgium (Project
EC UZG 2009/622).23 Also, approval of the local ethical com-
mittee of the Amsterdam UMC, Vrije Universiteit Amsterdam,
the Netherlands (Number 2014.322), and the Careggi Univer-
sity Hospital in Florence, Italy, (Protocol number 2013/
00016117, reference number 13/13 and 14/13) were obtained.
Informed consent was obtained from study participants accord-
ing to institutional guidelines.Treatment Protocol
The most common treatment of trans women consisted of
cyproterone acetate (CPA) 50 mg/d in combination with either
oral estradiol valerate 4 mg/d, transdermal estradiol patch 100
mg/24 h twice a week, or transdermal 0.06% estradiol gel (1.5
mg estradiol) once daily. Transdermal administration of estradiol
was recommended if trans women were >40 years old or if they
had a history of cardiovascular disease or thromboembolic events.
Spironolactone was used as an alternative antiandrogen if CPA
was contraindicated or not tolerated, for example because of
depressive symptoms. Some individuals only used estradiol
without an antiandrogen, for example, when they did not desire
gender reassignment surgery or orchiectomy.
Trans men received testosterone (T) in the form of either gel
(TG) 50 mg/d, long-acting intramuscular (im) testosterone
undecanoate (TU) 1000 mg once per 12 weeks (Nebido), or a
short-acting im testosterone ester (TE) mix of 250 mg once per 2
weeks (Sustanon). Individual adjustments of dosages at the start
of HT and thereafter were considered on a case-by-case basis.J Sex Med 2019;16:1297e1309
Table 1. Baseline characteristics and treatment regimens at start of hormonal treatment
Baseline characteristics Trans men Trans women
Number 193 205
Gender clinic, n
Amsterdam 132 123
Florence 5 2
Ghent 56 80
Filled out questionnaires, n
0 months 184 193
3 months 183 196
6 months 179 183
12 months 147 157
Age, y, median (IQR) 23 (20-31) 29 (22-43)
BMI, kg/m2, median (IQR) 23.5 (21.3-28) 22.8 (20.6-26.9)
Current smoker, no. (%)
No 118 (61.1%) 144 (70.2%)
Yes 62 (32.1%) 47 (22.9%)
Missing 13 (6.7%) 14 (6.8%)
Alcohol usage per week, no. (%)
7 units or less 170 (88.1%) 169 (82.4%)
8 units or more 8 (4.1%) 20 (9.8%)
Missing 17 (8.8%) 16 (7.8%)
Suppression of hormones at baseline,
no. (%)
Progestagens 57 (29.5%) NA
Hormone levels at baseline
Estradiol, pmol/L, median (IQR) 121 (61e236) 94 (76e120)
Testosterone, nmol/L, median
(IQR)
1.2 (0.9e1.6) 18.0 (14.0e22.2)
Hormone levels after start HT
Estradiol, pmol/L, median (IQR) 169 (118e233) 227 (141e330)
Testosterone, nmol/L, median
(IQR)
23.9 (16.3e36.0) 0.7 (0.5e1.0)
Treatment regimen at start of HT,
no. (%)
Testosterone gel 50 (25.9%) NA
Testosterone esters im 63 (32.6%) NA
Testosterone undecanoate im 62 (32.1%) NA
Missing 15 (7.8%) 15 (7.3%)
Estradiol tablets with CPA NA 110 (53.7%)
Estradiol tablet alone NA 2 (1.0%)
Estradiol patches or gel with CPA NA 75 (36.6%)
Estradiol patches or gel with
spironolactone
NA 1 (0.5%)
Estradiol patches or gel alone NA 2 (1.0%)
BMI ¼ body mass index; CPA ¼ cyproterone acetate; HT ¼ hormone therapy; im ¼ intramuscular; IQR ¼ interquartile range; NA ¼ not applicable.
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Data collection was performed at the outpatient expertise clinics
at baseline and at 3, 6, and 12 months of HT. At each visit, the
effects and side effects of HT and intercurrent diseases were evalu-
ated by an endocrine specialist, and HTwas adjusted if necessary. In
addition, body weight (in kilograms), length (in meters), body mass
index (calculated as kilograms divided by the square length), blood
pressure (in millimeters of mercury), tobacco use (as cigarettes per
day) and alcohol consumption (as units per week) were assessed.J Sex Med 2019;16:1297e1309Biochemical Assessment
Hormonal levels were measured at baseline and at 3 and 12
months of HT, and more frequently if indicated. A competitive
immunoassay (Delﬁa; PerkinElmer, Turku, Finland) was used
to measure estradiol levels in Amsterdam until July 2014, with
an interassay coefﬁcient of variation (CV) of 10e13% and a
lower limit of quantitation (LOQ) of 20 pmol/L. After July
2014, an LC-MS/MS (Amsterdam UMC, Amsterdam, the
Netherlands) was used, with a CV of 7% and a LOQ of 20
Figure 1. Items with transient symptom score changes during the ﬁrst 12 months of HT. o ¼ difference in symptom score compared to
baseline (0 months of HT) 0.2 for trans men; þ ¼ difference in symptom score compared with baseline (0 months of HT) 0.2 for trans
women; HT ¼ hormone therapy.
1300 van Dijk et alpmol/L. Levels were converted from Delﬁa values to LC-MS/
MS values using the formula LC-MS/MS ¼ 1.60 x Delﬁa-29.
In Amsterdam, until January 2013, testosterone levels were
measured with a radioimmunoassay (RIA) (Coat-A-Count;
Siemens, Los Angeles, CA, USA), with a CV of 7e20% and an
LOQ of 1 nmol/L. After January 2013, a competitive immu-
noassay (Architect; Abbott, Abbott Park, IL, USA) with a CV of
6e10% and an LOQ of 0.1 nmol/L. To convert RIA values to
the Architect values, for testosterone levels 8 nmol/L, the
formula Architect ¼ 1.1 * RIA þ 0.2 was used. For testosterone
levels >8 nmol/L, the formula Architect ¼ 1.34 * RIA  1.65
was used.
In Ghent, estradiol levels were measured using the Modular
E170 (Gen II; Roche Diagnostics, Mannheim, Germany) until
March 19, 2015. After March 19, 2015, the Modular E170
(Gen III; Roche Diagnostics) was used, with a CV of 3.2% and
LOQ of 92 pmol/L. Values were converted to Gen III values
using the formula Gen III ¼ 6.687940 þ 0.834495 * Gen II.
Testosterone was measured in Ghent using the Modular E170
(Gen II; Roche Diagnostics) with a CV of 2.6% and 0.4 nmol/L.
In Florence, all serum levels were measured using an electro-
chemiluminescence immunoassay (Modular Roche; Roche Di-
agnostics, Milan, Italy).Self-Reported Symptoms
Patients were asked to ﬁll out a questionnaire on symptoms
that could be related to HT, including psychovegetative symp-
toms (hot ﬂashes, night sweats, palpitations, dizziness, sleeping
difﬁculties, persisting fatigue), physical complaints (weight gain
>5 kg, abdominal complaints, change in olfactory sense and
balding, and for trans women also gum problems, dry skin or
itch and brittle nails, and for trans men also voice instability,
acne and edema), cognitive symptoms (memory loss and loss of
concentration), emotional and sexual symptoms (mood swings,
emotional instability, anxiety, fear, panic attacks, changes in
sexual desire), genital complaints for trans men (vaginal
discharge, spotting, persisting menses, vaginal dryness or itch),
and pain (headaches, migraine, breast tenderness, joint pain,
muscle or tendon pain, and, for trans men, pain in the pelvic area
and clitoral pain as well). The questionnaire consisted of 27 items
for trans women (Appendix A.1) and 33 items for trans men
(Appendix A.2). The questionnaire was unvalidated, self-
developed based on the Menopause Rating Scale and clinical
experiences with complaints mentioned during endocrinologic
consultations.
The questionnaires were ﬁlled out by the participants them-
selves at baseline and at 3 , 6, and 12 months of HT. SymptomsJ Sex Med 2019;16:1297e1309
Figure 2. Items for both trans men and trans women with persistent symptom score changes during the ﬁrst 12 months of HT. o ¼
difference in symptom score compared with baseline 0.2 (trans men); þ ¼ difference in symptom score compared with baseline 0.2
(trans women); HT ¼ hormone therapy.
Subjective Effects of Hormonal Treatment 1301were evaluated using a 4-point Likert scale (no [0], mild [1],
moderate [2], or severe [3] complaints). The questionnaire was
written in Dutch (Amsterdam and Ghent) or Italian (Florence).Statistical Analyses
Baseline characteristics are expressed as percentages or as me-
dian with interquartile ranges (IQR). When reporting symptoms,
a score of 1, 2, or 3 (mild, moderate or severe) was considered as
experiencing the symptom in any degree.
Linear mixed models with measurements clustered within
participants within centers were used to analyze changes in
symptom score intensity during the ﬁrst treatment year and to
adjust for missing values.24 Time was as added categorical vari-
able to detect changes in symptom scores between 0e3 months,
0e6 months, and 0e12 months of HT.
Changes in mean symptom scores were presented as co-
efﬁcients (b) with 95% CI. Differences in changes in symptom
scores between different administration forms were corrected for
baseline differences to avoid regression to the mean. An increase
or decrease in symptom scores of 0.2 was considered clinically
relevant. All analyses were performed using Stata, version 15.1J Sex Med 2019;16:1297e1309(StataCorp LP, College Station, Texas, USA).RESULTS
Study Population and Hormonal Treatment
Regimen
A total of 205 trans women and 193 trans men who had
ﬁnished their ﬁrst year of HT and had ﬁlled out at 1 symptom
questionnaire were included in this study. Baseline characteristics
and hormonal regimen started at baseline are presented in
Table 1.Subjective Effects
Baseline symptom scores and changes in scores are presented
in Appendix B.1 for trans men and Appendix B.2 for trans
women. Because of the large amount of items, only items with a
transient change (Figure 1) or persistent change (Figures 2e4) in
symptom score are presented in the ﬁgures. Figure 5 shows the
symptom score changes in the ﬁrst 3 months for different
administration routes. Table 2 summarizes the items that
changed persistently, temporarily, or did not change during 12
months of HT.
Figure 3. Items for trans men with persistent symptom score changes during the ﬁrst 12 months of HT. o ¼ difference in symptom score
compared with baseline 0.2; HT ¼ hormone therapy.
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Psycho Vegetative Symptoms
Night sweat scores were transiently increased at 6 months
(þ0.20, 95% CI 0.06e0.35), but normalized thereafter
(Figure 1). Hot ﬂashes increased during the ﬁrst 3 months of HT
(þ0.39, 95% CI 0.26e0.53) and persisted to be increased after
12 months of HT, compared with baseline scores (þ0.35, 95%
CI 0.21e0.49) (Figure 2).
Palpitations, dizziness, sleeping difﬁculties, and persistent fa-
tigue did not change (Appendix B.1). In the ﬁrst 3 months, nosigniﬁcant differences between testosterone administration routes
were observed (Appendix B.1).
Physical Complaints
Weight gain of5 kg (Figure 1) was reported by 44.4% of trans
men after 3 months of HT, with an increase in symptom scores
of þ0.57 (95% CI 0.43e0.72). After 12 months of HT, the
symptom score difference with the baseline score wasþ0.19 (95%
CI 0.04e0.35). The largest increase in weight gain symptoms
scores was reported by trans men using TE compared with TG and
TU, but this difference was not signiﬁcant (þ0.85, 95%CI0.01J Sex Med 2019;16:1297e1309
Figure 4. Items for trans women with persistent symptom score changes during the ﬁrst 12 months of HT. þ ¼ difference in symptom
score compared with baseline 0.2; HT ¼ hormone therapy.
Subjective Effects of Hormonal Treatment 1303to 1.70). Balding (Figure 2) increased after 12 months of HT
with þ0.25 (95% CI 0.16e0.33). Acne scores peaked after 6
months of HT (þ0.76, 95% CI 0.62e0.90) and were still higher
compared with baseline after 12 months of HT (þ0.71, 95% CIJ Sex Med 2019;16:1297e13090.56e0.85) (Figure 3). Voice instability scores (Figure 3) peaked
at 3 months (þ1.20, 95% CI 1.06e1.35) and decreased there-
after, but higher scores compared with baseline were reported after
12 months (þ0.56, 95% CI 0.41e0.71). A smaller symptom
Figure 5. Items with differences in symptom score changes in the ﬁrst 3 months between different administration routes of HT (adjusted
for baseline differences). HT ¼ hormone therapy.
1304 van Dijk et alscore increase in the ﬁrst 3 months was reported for TU compared
with TG (difference1.08, 95%CI1.98 to0.19), but not for
TE (Figure 5).
No differences were reported for abdominal complaints, a
change in olfactory sense and edema (Appendix B.1). Except for
voice instability, no differences were observed between testos-
terone administration routes (Appendix B.1).
Cognition
No clinically relevant changes in symptom scores in memory
loss and loss of concentration were reported (Appendix B.1).
Emotionality and Sexuality
During 12 months of HT, no differences were observed in
mood swings, anxiety and panic attacks (Appendix B.1).
Emotional instability scores (Figure 2) decreased persistently
compared with baseline (0.23, 95% CI 0.35 to 0.11).
Decreased scores for fear (Figure 3) were reported after 12
months of HT (0.25, 95% CI 0.35 to 0.15).
Lower scores for a decrease in sexual desire were reported after
3 months of HT (0.28, 95% CI 0.39 to 0.10) and were
still decreased after 12 months of HT (0.20, 95% CI 0.32to 0.08). A persistent increase in sexual desire was reported
(Figure 3), with a peak after 3 months (þ1.37, 95% CI
1.21e1.52). Scores decreased thereafter but were still higher
compared with baseline after 12 months (þ1.04, 95% CI
0.88e1.21). The largest increases in sexual desire were reported
in TE using trans men compared with TG and TU in the ﬁrst 3
months (difference þ1.30, 95% CI 0.66e1.93) (Figure 5).
When comparing different testosterone administration routes, no
signiﬁcant differences were observed in the ﬁrst 3 months
(Appendix B.1), except for an increase in sexual desire (Figure 5).
Genital Complaints
Cessation of menses (Figure 3) occurred after 6 months of HT
and thereafter (0.32, 95%CI 0.45 to 0.19). No signiﬁcant
differences between administration routes were observed
(Appendix B.1).
No clinically relevant changes were observed for spotting and
vaginal discharge, but when comparing TE and TU to TG, TU
showed larger increases in symptom scores after 3 months of HT
for spotting (þ0.77, 95% CI 0.05e1.49). Vaginal discharge
scores were reported to be lower for TU compared with TG and
TE (0.82, 95% CI 1.61 to 0.04). No change in symptomJ Sex Med 2019;16:1297e1309
Table 2. Summary of symptom changes for both trans men and trans women, trans men only and trans women only
Area
Trans men and/
or trans women No change Temporarily Persisting
Psycho vegetative
symptoms
Both Palpitations, dizziness — Hot ﬂashes [
Trans men Persisting fatigue Night sweats [ —
Trans women - Sleeping difﬁcultiesY Night sweats, * persisting
fatigue [
Physical complaints Both Abdominal complaints — —
Trans men Change in olfactory sense,
edema
Weight gain [ Balding, voice instability, *
acne [
Trans women Gum problems, dry skin or
itch*
— Weight gain, change in
olfactory sense, brittle nails
[, baldingY
Cognition Both Memory loss, concentration
loss
— —
Emotionality and sexuality Both Anxiety, panic attacks — —
Trans men Mood swings — Decrease in sexual desire,
emotional instability, fearY,
increase in sexual desire*[
Trans women Increase in sexual desire, fear — Mood swings, emotional
instability, decrease in
sexual desire [
Genital complaints Trans men Vaginal discharge,* spotting,
* vaginal dryness or itch
— Persisting mensesY
Pain Both Headache, migraine, joint
pain
—
Trans men Breast tenderness, muscle-
and tendon pain, pelvic pain
Clitoral pain*[ —
Trans women Muscle- and tendon pain* — Breast tenderness [
[ ¼ increase in symptom score; Y ¼ decrease in symptom score.
*Signiﬁcant difference between administration routes in the ﬁrst 3 months.
Subjective Effects of Hormonal Treatment 1305scores were observed for vaginal dryness or itch, neither were
signiﬁcant differences observed between different testosterone
administration routes (Appendix B.1).
Pain
A transient increase in clitoral pain (Figure 1) was observed
(þ0.26, 95% CI 0.18e0.34 after 3 months and þ0.21,
95% CI 0.03e0.22 after 6 months), with the largest in-
creases for TE compared with TG and TU in the ﬁrst 3
months (difference þ0.36, 95% CI 0.04e0.69). Symptom
scores for headaches, migraine, breast tenderness, joint pain,
muscle or tendon pain, and pelvic pain did not show
changes considered clinically relevant. No signiﬁcant differ-
ences between the different administration routes were
observed.
Progestagen Use
No differences in symptom score changes were found be-
tween trans men who used progestogens at baseline and those
who did not.J Sex Med 2019;16:1297e1309Trans Women
Psycho Vegetative Symptoms
Symptom scores of hot ﬂashes (Figure 2) and night sweats
(Figure 4) increased after 3 months of HT and persisted to be
higher at 12 months of HT (þ0.45, 95% CI 0.32e0.58 for
hot ﬂashes, and þ0.48, 95% CI 0.34e0.62 for night sweats).
Trans women using transdermal estradiol reported a larger in-
crease in night sweat scores compared with oral use in the ﬁrst
3 months (þ0.26, 95% CI 0.03e0.49) (Figure 5), even when
corrected for baseline differences and age. Persisting fatigue
scores (Figure 4) showed an increase at 3 months and kept
increasing thereafter until 12 months of HT (þ0.53, 95% CI
0.40e0.67). Sleeping difﬁculty symptom scores showed a
temporary decrease at 3 months of HT (0.20, 95% CI 0.32
to 0.07) (Figure 1).
No change was observed in dizziness and palpitations
(Appendix B.2). Except for night sweats, no differences were
observed in the ﬁrst 3 months of HT between oral and trans-
dermal administration (Appendix B.2).
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Weight gain was reported by 26.3% of trans women in the
ﬁrst 3 months of HT. Symptom scores were increased after 3
months of HT, and scores were still higher after 12 months of
HT (þ0.29, 95% CI 0.16e0.41) (Figure 4). Symptom scores
of a change in olfactory sense (Figure 4) showed a persistent
increase after 6 months of HT, with the highest score after 12
months (þ0.30, 95% CI 0.20e0.39). Balding symptom scores
(Figure 2) decreased persistently after 3 months of HT, with
the largest decrease in the ﬁrst 6 months of HT (0.50, 95%
CI 0.61 to 0.38). Brittle nail symptom scores (Figure 4)
were increased at 12 months of HT (þ0.24 95% CI
0.12e0.36).
Symptom scores for abdominal complaints, gum problems
and a dry skin or itch did not show clinically relevant changes
(Appendix B.2). Apart from a larger symptoms score increase in
scores for dry skin or itch for transdermal estradiol compared
with oral administration after 3 months of HT (þ0.22, 95%
CI 0.02e0.42), no differences in symptoms score changes be-
tween oral and transdermal administration were observed
(Appendix B.2).
Cognition
No clinically relevant changes in symptom scores for memory
and concentration loss were reported (Appendix B.2).
Emotionality and Sexuality
Emotional instability (Figure 2) and mood swing (Figure 4)
symptom scores increased persistently during the ﬁrst 12
months of HT. Emotional instability scores peaked after 3
months of HT compared with baseline (þ0.43, 95% CI
0.30e0.57), whereas mood swing scores were maximally
increased after 6 months of HT (þ0.30, 95% CI 0.16e0.44).
The symptom scores for a decrease in sexual desire (Figure 2)
peaked after 3 months of HT (þ1.41, 95% CI 1.23e1.60) and
decreased thereafter but were still increased compared with
baseline after 12 months of HT (þ1.08, 95% CI 0.89e1.28).
After 12 months of HT, no clinically relevant changes in scores
for an increase in sexual desire, anxiety, fear, or panic attacks
and no signiﬁcant differences between administration routes
were observed (Appendix B.2).
Pain
Breast tenderness (Figure 4) peaked at 3 months (þ1.52,
95% CI 1.38e1.66), and this persisted during the ﬁrst 12
months of HT. No change was observed for headaches,
migraine, joint pain, and muscle and tendon pain (Appendix
B.2). When comparing estradiol administration routes, an in-
crease was seen for muscle or tendon pain scores for trans-
dermal administration, whereas the scores for oral intake did
not change in the ﬁrst 3 months of HT (difference þ0.21,
95% CI 0.04e0.38).DISCUSSION
This study describes self-reported symptoms experienced by a
large cohort of trans people during the ﬁrst year of HT. Both
trans men and trans women reported changes in symptoms
within all investigated areas, except for cognition.
In our current study, we found more reported side effects than
in the previous study by Wierckx et al.22 In the smaller cohort,
no increases in fatigue, hot ﬂashes in trans men, or night sweats
in both trans men and women were reported, although we did
ﬁnd increases in the current larger cohort. This might be caused
by the difference in cohort size. Another explanation could be
found in the analysis, because they studied prevalence, whereas
we calculated symptom score changes over time to estimate the
changes in intensity of symptoms.
For trans women, there was an expected cessation of scalp hair
loss. Trans women using transdermal estradiol had higher base-
line scores. This may be caused by age. Trans women starting
with transdermal administration had a median age of 44 years
(IQR 28e50), whereas the trans women starting with oral
administration had a median age of 25 years (IQR 20e33). This
age difference is not surprising, because, with increasing age,
trans women are advised to start with or switch to transdermal
administration to reduce the risk for venous thrombosis. After
correction for this baseline difference, no differences between
administration routes were present.
Another, not completely unexpected, reported symptom in
trans women was the change in olfactory sense, because the ef-
fects of estrogens on olfactory function have been reported
during the hormonal ﬂuctuations within the menstrual cycle,
hormonal contraceptive use, and hormone replacement therapy
in postmenopausal women.25,26
Fatigue is a known side effect of oral cyproterone acetate.27,28
Therefore, it is not unexpected that trans women reported an
increase in persisting fatigue. It is not completely understood
whether this is the result of androgen deprivation alone or a
combination with other factors, such as a side effect of the CPA
tablets and psychosocial factors during a gender-afﬁrming pro-
cedure. Only 2% in our cohort started estradiol alone, and only 1
participant used spironolactone as an antiandrogen. It would be
interesting to collect data from a larger cohort of trans women
not using CPA to assess the contribution of CPA to symptoms
experienced during HT. Also, future clinical trials are needed to
compare effects of different antiandrogens, such as CPA, spi-
ronolactone, and gonadotropin-releasing hormone analogues on
fatigue, but also on other symptoms and side effects, including
depressive symptoms.
In trans men, the questionnaire included items on genital
complaints. As anticipated, testosterone treatment had a pro-
found effect on the menstrual cycle.22 Most trans men experi-
enced a cessation of the menses within the ﬁrst 6 months onJ Sex Med 2019;16:1297e1309
Subjective Effects of Hormonal Treatment 1307testosterone. Higher scores for persisting menses in the ﬁrst 3
months were observed for TU; however, this was not signiﬁcant.
A possible explanation may be that not all trans men starting TU
did receive a loading dose after 6 weeks, causing lower testos-
terone levels 12 weeks after injection. Testosterone levels were
available; however, no information was available on the moment
of injection. This made the interpretation of complaints in
relation to testosterone levels difﬁcult, and, therefore, we chose
not to correlate this to the questionnaire items.
Affective and anxiety disorders are not rare among gender-
afﬁrming treatmenteseeking trans people.29 Several studies
show HT improves depressive symptoms and anxiety scores in
trans people.2e4,30 We observed a decrease in fear and emotional
instability in trans men, whereas emotional instability and mood
swings increased in trans women. To the best of our knowledge,
emotional instability and mood swings are only studied in the
small sample of the European Network for the Investigation of
Gender Incongruenceeendocrinology cohort.22
Literature on the cognitive effects of HT is limited and often
suffers from methodologic limitations, such as small sample sizes
or a lack of pretreatment data.31 Some studies in trans women
using estrogens show an improvement in (aspects of) short-term
memory, whereas others did not ﬁnd consistent effects.16,32,33 In
our study, no change was observed in loss of concentration or
memory loss scores for both trans women and trans men.
Clearly, these areas are difﬁcult to measure with 1 or 2 simple
questions and are only explorative. To draw robust conclusions
about these topics, studies with validated psychological in-
struments are necessary.
Another investigated area was pain. Only 1 study, by Aloisi
et al,21 speciﬁcally evaluated pain syndromes in trans people who
were using HT for 1 year. Painful breasts was a common
complaint in trans women, in line with our results showing an
increase in breast tenderness at 3 months of HT.
Also in line with Aloisi et al,21 trans men in our cohort
reported muscle, tendon and joint pain more frequently after
the start of HT. However, we did not ﬁnd clinically relevant
increases in symptom scores. In the future, it would be
interesting to investigate further these complaints in trans men
and trans women and to link these subjective symptoms to
hormonal levels and objective parameters, such as muscle mass
and grip strength.Limitations
Some limitations of our study should be noted. First, we used
a non-validated questionnaire to evaluate self-reported side ef-
fects, because no such validated questionnaire including all these
varying symptoms exists. Next, some parts of the questionnaire
were open to the participants’ interpretation; for example,
emotional instability and mood swings may be difﬁcult to
distinguish. Additionally, the follow-up of this study was 12
months. During this follow-up period, a decreasing number ofJ Sex Med 2019;16:1297e1309participants completed the questionnaire because of a loss to
follow-up. Because a part of the trans men had a phased start
with progestogens only during the ﬁrst period of HT, and
questionnaires were only used from the visit testosterone was
started, and, thereafter, this resulted in the absence of available
questionnaires at 12 months of testosterone.
For some effects, it can be expected that symptoms might
improve or worsen after the timespan of 12 months. A longer
follow-up period is needed to study the effects during a longer
period of HT. Also, the explorative character of the questionnaire
only provided on the occurrence of symptoms, and every item
deserves to be studied in full detail with validated questionnaires.
Because no information is available on the effect of the symp-
toms on the quality of life, it would be interesting to further
study this topic. Trans people should be involved in this process
to strengthen and conﬁrm the trans people’s perspective and
experiences in HT.
Because a major part of the participants switched adminis-
tration route during the 12 months of follow-up, the inﬂuence of
the total treatment period with a certain administration route,
and the possibility that symptoms were the reason to switch, we
only studied the administration routes in the ﬁrst 3 months in an
explorative way.
However, our results are a valuable addition to the current
knowledge of HT in trans people. It is the ﬁrst study that sys-
tematically and prospectively investigated the occurrence of a
wide variety of subjective effects of HT in a large cohort of 398
trans individuals. Furthermore, most of the included trans people
in this study have been treated according to a similar protocol,
making comparison of results to current and future research
possible. These results can contribute to a better quality of care
and enable clinicians to give information to their patients
regarding the expected pattern of symptoms after starting with
HT.CONCLUSION
In conclusion, both trans men and trans women in this study
reported changes in symptoms within all investigated areas
during the ﬁrst year of hormonal treatment, except for cognition.
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